November 20, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOVENTOC venetoclax 100mg) tablets for the treatment ofchronic lymphocytic leukemia (CLL) .
Venetoclax (brand name Venclexta) is a prescription medication used for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). It is an oral small molecule inhibitor that targets the B-cell lymphoma 2 (BCL-2) protein, which is overexpressed in some types of cancer cells and contributes to their survival. By inhibiting BCL-2, venetoclax induces cancer cell death, leading to the regression of tumors.
BIOVENTOC "Formulation Manufacturing" by BioSpring.LTD through "Third Party Manufacturing" business model. The product is expected to be delivered to customers in the end of decermber. BIOVENTOC is registered in Timor-Leste by its global clients, The registration number is Reg.N.° 274945523tl. We wish this product every success in the global market and hope that it will create an image for the company and increase exports.
Pharma Third party manufacturing/contract manufacturing provide easy solution for manufacturing of own brands.
Third party or contract manufacturing is referred to outsourcing of products or to get manufactured one’s brand names from others manufacturing unit out. In current time it is very popular concept among marketing companies. Even companies having their own manufacturing units are gotten manufactured their products from outside. Multinational companies are also gotten manufactured their products at loan license or third-party basis.
Founded in 2022 at the Vientiane Saiseta Comprehensive Development Zone in Laos, BioSpring is the country's fastest growing generic drug manufacturing company and the country's first pharmaceutical company targeting the international market, serving Asia, Africa, Europe and Latin America Americas and many other countries and regions.
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.
April 03, 2023, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOLANI (Olapanib 50mg) capsules for the treatment cancer. Olaparib, a medication used in the treatment of cancer. Olaparib is a PARP inhibitor, which means that it inhibits the activity of the PARP enzyme, an enzyme involved in DNA repair. By inhibiting PARP, olaparib can prevent cancer cells from repairing…
Trametinib and dabrafenib are prescription medications used in combination to treat a specific type of skin cancer called melanoma that has a specific mutation called BRAF V600E or V600K. Dabrafenib is a selective inhibitor of mutated BRAF kinases, which are involved in cell growth and survival. Trametinib is a selective inhibitor of MEK, which is a downstream target of BRAF…
November 07, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOMOB (Mobocertinib 40mg) capsules for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutation. Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.Mobocertinib is an irreversible kinase inhibitor, forming a covalent…
